View Clinical Trial (Medical Research Study)

Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE) - NCT00987831-73104(Clinical Trial 353352)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Oklahoma City
State:  
OK
Zip Code: 73104
Conditions: Systemic Lupus Erythematosus
Purpose: Hypothesis: A reason for repeated disappointing outcomes of clinical trials testing targeted immune biologics for lupus may be the heterogeneity of the disease, exacerbated by the variable effects on immune homeostasis of the background medications that must be continued, in most study designs, in these flare-prone patients. Purpose of Study: This study will purposefully study a population equivalent to the placebo group of typical trials in SLE. Patients will enter the trial in mild-moderate flare, be treated with depomedrol, and background treatments will be withdrawn. Biomarkers at entry on various medications will be compared to biomarkers after steroid efficacy with background medications withdrawn. Depomedrol usually slowly wears off over one to three months. Patients will be closely observed, with serial biomarkers drawn at monthly intervals or, immediately at the time of a new flare. Those patients who do develop new flares during the course of the next year (maximal participation time) will donate blood samples for biomarkers (flaring on tapering or absent depomedrol effect) and will then be immediately treated as deemed appropriate, exiting the study. The study will end when 50 patients have met this endpoint. A control population of matched, healthy individuals will donate blood once for the same biomarker studies.
Study summary: Patients with at least a SLEDAI score of 6 or a BILAG score of B in at least two organ systems or A in at least one organ system will be immediately entered into this study once informed consent is obtained. Background immune suppressants (if any) are stopped and in half of the patients hydroxychloroquine will also be stopped. All patients will immediately receive a shot of depomedrol 160 mg IM. Over the next two weeks they may elect up to three more shots of depomedrol for a total of four shots by the two week visit period. A complete battery of blood tests to assess lupus disease is drawn at the screening visit, and monthly thereafter. Biomarker studies are drawn as often as weekly for some markers and as often as three times in the study (landmark visits) for others. Landmark visits are defined as: 1.) screening (pre-dose, on background meds with active disease) 2.) two weeks or four weeks after screening as optimal to assess a patient who has stopped background meds and is now maximally improved (but at least one grade drop in BILAG scores in all organs entered at A or B or a four point drop in SLEDAI, otherwise the participant is deemed a treatment failure and will be replaced in the study). 3.) Flare visit on no background immune suppression and 1/2 on no hydroxychloroquine either, defined as the monthly visit or interim visit at which the patient has an increase in SLEDAI of 4 points from maximal improvement or has increased back to at least two BILAG B scores or at least one BILAG A scores.Patients will be seen within 3 days if flare occurs between monthly scheduled visits. The following biomarkers are being obtained: cytokine panel, B Cell studies, T Cell studies, autoantibody profiles, epigenetic and gene expression studies and flow cytometry studies.
Criteria: Inclusion Criteria: Active Groups: 1. ACR criteria for SLE. 2. At least two organ systems moderately active to a minimum of BILAG B or SLEDAI score of 6. Control group: 1. Age, ethnicity and gender matched (2:1) with an active trial participant. 2. Free of active or major chronic disease and taking no immune suppressive or anti-inflammatory medications. Exclusion Criteria: 1. Safety or circumstantial reasons why volunteer cannot comply with the protocol.
Study is available at: Oklahoma Medical Research Foundation
Oklahoma City, OK 73104
United States

Primary Contact:
Fredonna Carthen
Email: fredonna-carthen@omrf.org
Phone: 405-271-7805

Secondary Contact:
Fredonna Carthen
Email: fredonna-carthen@omrf.org
Phone: 405-271-7805
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.